Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06822426 · ClinicalTrials.gov registry record · Phase 3
Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)
A Phase 3 study of Central Line Associated Blood Stream Infections (CLABSI), sponsored by CorMedix.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
- 15
- Study locations
NCT06822426: Recruiting Phase 3 study of Central Line Associated Blood Stream Infections (CLABSI), sponsored by CorMedix.
NCT06822426 is a Phase 3 study of Central Line Associated Blood Stream Infections (CLABSI) that is actively recruiting participants, run by CorMedix. The registered enrollment target is 200 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (74% lower). The trial reports 15 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06822426, a Phase 3 study of Central Line Associated Blood Stream Infections (CLABSI), is actively recruiting participants, sponsored by CorMedix.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is a Phase 3, randomized, double-blind, controlled, adaptive, 2-arm, multicenter study to demonstrate the efficacy and safety of DefenCath in adult participants receiving home Total Parenteral Nutrition (TPN) via Central Venous Catheter (CVC) compared with heparin.
Primary Outcome
The proportion of participants who remain infection-free in the treatment groups will be compared, censoring participants who do not experience a CLABSI within 9 months, but fail to complete the 12 month follow-up period of the study.
Conditions Studied
Interventions
- DRUG Heparin
- DRUG (taurolidine and heparin) catheter lock solution
Study Locations (15)
California
- University of California Los Angeles - Los Angeles
District of Columbia
- MedStar Health Research Institute - Washington D.C.
Florida
- Bioresearch Partner - Doral
Georgia
- Emory University Hospital - GCRC - Atlanta
Iowa
- University of Iowa Health Care - Iowa City
Maryland
- Johns Hopkins Clinical Research Unit - Baltimore
Minnesota
- Mayo Clinic - Rochester
Nebraska
- University of Nebraska Medical Center - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-05-14 |
| Est. Completion | 2027-01 |
| Phase | Phase 3 |
What NCT06822426 shows while recruiting
NCT06822426 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Central Line Associated Blood Stream Infections (CLABSI) appearing as the primary indexed condition, and to 2 interventions - of which Heparin is the first listed.
NCT06822426 lists 15 locations in 15 states (California, District of Columbia, Florida).
Frequently Asked Questions
What is clinical trial NCT06822426 about?
NCT06822426 is a clinical study titled "Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)". This is a Phase 3, randomized, double-blind, controlled, adaptive, 2-arm, multicenter study to demonstrate the efficacy and safety of DefenCath in adult participants receiving home Total Parenteral Nutrition (TPN) via Central Venous Catheter (CVC) compared with heparin.
What is the current status of trial NCT06822426?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2025-05-14. Estimated completion is 2027-01.
What conditions does trial NCT06822426 study?
This clinical trial studies the following conditions: Central Line Associated Blood Stream Infections (CLABSI).
What interventions are being tested in trial NCT06822426?
The interventions under investigation include: Heparin (DRUG), (taurolidine and heparin) catheter lock solution (DRUG).
Who is sponsoring clinical trial NCT06822426?
This trial is sponsored by CorMedix, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06822426 being conducted?
This trial has 15 study locations across California, District of Columbia, Florida, Georgia, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Central Line Associated Blood Stream Infections (CLABSI)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06822426's enrollment target sits among peer trials
200 1354th of 2000 higher than 613 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI